Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs
Satoshi Watanabe1, O U Yamaguchi2, A I Masumoto2
1Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Background/Aim:
Promising reports have described the combination of first-generation epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) with carboplatin plus pemetrexed or bevacizumab. However, no analysis of afatinib with platinum-doublet chemotherapies has been performed.
Patients And Methods:
We evaluated the safety and antitumor efficacy of afatinib combined with carboplatin and pemetrexed in EGFR-mutated non-small-cell lung cancer (NSCLC) patients who progressed during first-generation EGFR-TKIs.
Results:
Ten patients received 20 or 30 mg/day afatinib with carboplatin (area under the curve, 5) and pemetrexed (500 mg/m2). Dose-limiting toxicities included delay of afatinib ≥14 days, grade 3 diarrhea, grade 3 hypokalemia, grade 3 serum amylase increase and grade 4 thrombocytopenia. The recommended dose of afatinib was 20 mg/day in this combination therapy. Overall response rate was 30% and median progression-free survival was 13.7 months.
Conclusion:
This is the first study to investigate the combination of afatinib, carboplatin and pemetrexed. At the recommended dose, this combination was well tolerated and had a good clinical efficacy.
Insights
Afatinib combined with carboplatin and pemetrexed showed good clinical efficacy in EGFR-mutated non-small-cell lung cancer patients. The recommended dose of 20 mg/day afatinib was well tolerated, with a 30% overall response rate.
Area of Science:
- Oncology
- Pharmacology
- Medical Research
Background:
- Previous studies explored first-generation EGFR-TKIs with chemotherapy.
- No prior analysis investigated afatinib with platinum-doublet chemotherapy.
Purpose of the Study:
- To assess the safety and efficacy of afatinib combined with carboplatin and pemetrexed.
- To determine the recommended dose for this combination therapy in EGFR-mutated NSCLC patients post-first-generation EGFR-TKI progression.
Main Methods:
- A study involving ten EGFR-mutated non-small-cell lung cancer (NSCLC) patients.
- Patients received varying doses of afatinib (20 or 30 mg/day) along with carboplatin and pemetrexed.
- Safety and antitumor efficacy were evaluated.
Main Results:
- Recommended afatinib dose identified as 20 mg/day due to dose-limiting toxicities at higher doses.
- Observed dose-limiting toxicities included diarrhea, hypokalemia, elevated serum amylase, and thrombocytopenia.
- Achieved an overall response rate of 30% and a median progression-free survival of 13.7 months.
Conclusions:
- This is the first study to evaluate the combination of afatinib, carboplatin, and pemetrexed.
- The combination therapy, at the recommended dose, demonstrated good tolerability.
- The regimen showed promising clinical efficacy in the studied patient population.
Related Concept Videos
Phase Diagrams
Phase Transitions
Inductance: Single-Phase And Three-Phase Line
Single-Phase Two-Wire Line:
A single-phase line consists of two solid cylindrical conductors, denoted as x and y. Each conductor carries phasor currents ix and iy, respectively. Given that the sum of these currents is...
Capacitance: Single-Phase And Three-Phase Line
Single-Phase Lines
Consider a single-phase, two-wire transmission line with equal phase spacing energized by a voltage source. One conductor carries a uniform positive charge, while the other carries an equal negative charge. The capacitance C of the line can be derived from the voltage V between the conductors. For a one-meter section of the line, the capacitance is given...
Phase Changes
A substance melts or freezes at a temperature called its melting point and boils or condenses at its boiling point. These temperatures depend on pressure. High pressure favors the denser form of the substance, so typically, high pressure...
Phase-lead and Phase-lag Controllers


